The literature on risk factors for cardiometabolic diseases showed that lutein might be beneficial for atherosclerosis and inflammatory markers , but there were inconsistent associations with blood pressure , adiposity , insulin resistance , and blood lipids .
CONCLUSIONS Our findings suggest that higher dietary intake and higher blood concentrations of lutein are generally associated with better cardiometabolic health .
BACKGROUND The antioxidant lutein is suggested as being beneficial to cardiometabolic health because of its protective effect against oxidative stress , but evidence has not systematic ally been evaluated .
OBJECTIVE We aim ed to evaluate systematic ally the effects of lutein ( intake or concentrations ) on cardiometabolic outcomes in different life stages .
Plasma lycopene, other carotenoids, and retinol and the risk of cardiovascular disease in men.
BACKGROUND Emerging evidence suggests a possible role of lycopene in the primary prevention of cardiovascular disease ( CVD ) . OBJECTIVE We examined whether plasma lycopene concentrations in the Physicians ' Health Study were associated with CVD in a prospect i ve , nested , case-control design . DESIGN Baseline blood sample s were collected starting in 1996 . During a mean follow-up of 2.1 y , we identified 499 cases of CVD ( confirmed myocardial infa rct ion , stroke , CVD death , or revascularization procedures ) and an equal number of men free of CVD and matched for age ( x : 69.7 y ) , follow-up time , and smoking status . We collected self-reported coronary disease risk factors and measured plasma carotenoids , retinol , lipids , and C-reactive protein . RESULTS In matched analyses with additional adjustment for plasma total cholesterol and r and omized treatment , the relative risks ( RRs ) of CVD for men in the lowest to highest quartiles of plasma lycopene were 1.00 ( reference ) , 0.92 , 1.04 , and 0.95 ( P for linear trend = 0.93 ) . With multivariate adjustment , the RRs of total CVD were 1.00 ( reference ) , 1.08 , 0.94 , and 1.03 ( P for linear trend = 0.98 ) . For important vascular events ( 241 cases ) , excluding revascularization procedures , the multivariate RRs remained nonsignificant ( P for linear trend = 0.50 ) . Adding plasma carotenoids , lipids , or C-reactive protein to multivariate models had a minimal effect on the RRs of total CVD for plasma lycopene . Compared with lycopene , higher concentrations of plasma lutein/zeaxanthin and retinol suggested a moderate increase in CVD risk , whereas no association was found for beta-cryptoxanthin , alpha-carotene , and beta-carotene . CONCLUSIONS Higher plasma lycopene concentrations were not associated with the risk of CVD in this study of older men . Further evaluation in diverse population s is necessary
The literature on risk factors for cardiometabolic diseases showed that lutein might be beneficial for atherosclerosis and inflammatory markers , but there were inconsistent associations with blood pressure , adiposity , insulin resistance , and blood lipids .
CONCLUSIONS Our findings suggest that higher dietary intake and higher blood concentrations of lutein are generally associated with better cardiometabolic health .
BACKGROUND The antioxidant lutein is suggested as being beneficial to cardiometabolic health because of its protective effect against oxidative stress , but evidence has not systematic ally been evaluated .
OBJECTIVE We aim ed to evaluate systematic ally the effects of lutein ( intake or concentrations ) on cardiometabolic outcomes in different life stages .